1.0Achucarro Basque Center for Neurosciencehttps://www.achucarro.org/eu/rich600338<blockquote class="wp-embedded-content" data-secret="tl3v4GkHL4"><a href="https://www.achucarro.org/eu/mintegia/2025-12-jordi-bonaventura/">Neurochemical Cross-Talk: How Glutamate, Dopamine, and Opioids Drive Ketamine’s Actions</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://www.achucarro.org/eu/mintegia/2025-12-jordi-bonaventura/embed/#?secret=tl3v4GkHL4" width="600" height="338" title="“Neurochemical Cross-Talk: How Glutamate, Dopamine, and Opioids Drive Ketamine’s Actions” — Achucarro Basque Center for Neuroscience" data-secret="tl3v4GkHL4" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://www.achucarro.org/wp-includes/js/wp-embed.min.js </script> Esketamine represents a novel approach to mood disorder treatment, acting through mechanisms distinct from traditional monoaminergic antidepressants by targeting N-methyl-D-aspartate receptors (NMDARs). However, its pharmacological profile is complex, given its relatively low affinity for NMDARs and additional interactions with other targets, including opioid receptors. The precise mechanisms underlying its antidepressant effects—and its potential for misuse—remain […]